BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld MedTech
Home
» Diabetic Foot Ulcer Market: Omnigraft approval seen as catalyst for Integra, DFU market
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Diabetic Foot Ulcer Market: Omnigraft approval seen as catalyst for Integra, DFU market
Jan. 11, 2016
By
Amanda Pedersen
No Comments
A new FDA approval is expected to be an important catalyst for Integra Lifesciences Corp. (Plainsboro, N.J.) and represents a step in the right direction for the broader diabetic foot ulcer (DFU) market.
BioWorld MedTech